271 related articles for article (PubMed ID: 33342311)
21. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
[TBL] [Abstract][Full Text] [Related]
22. Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
Mize CD; Abbott AM; Gacasan SB; Parrill AL; Baker DL
J Mol Graph Model; 2011 Nov; 31():76-86. PubMed ID: 21967734
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
24. Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.
Dong YL; Duan XY; Liu YJ; Fan H; Xu M; Chen QY; Nan Z; Wu H; Deng SJ
Inflammation; 2019 Oct; 42(5):1530-1541. PubMed ID: 31102124
[TBL] [Abstract][Full Text] [Related]
25. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
Zagórska A
Expert Opin Ther Pat; 2020 Feb; 30(2):147-157. PubMed ID: 31874060
[No Abstract] [Full Text] [Related]
27. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells.
Nikitopoulou I; Fanidis D; Ntatsoulis K; Moulos P; Mpekoulis G; Evangelidou M; Vassiliou AG; Dimakopoulou V; Jahaj E; Tsipilis S; Orfanos SE; Dimopoulou I; Angelakis E; Akinosoglou K; Vassilaki N; Tzouvelekis A; Kotanidou A; Aidinis V
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576169
[TBL] [Abstract][Full Text] [Related]
28. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
29. Design and Development of Autotaxin Inhibitors.
Jia Y; Li Y; Xu XD; Tian Y; Shang H
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832985
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
[TBL] [Abstract][Full Text] [Related]
31. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
33. Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.
Herr DR; Chew WS; Satish RL; Ong WY
Mol Neurobiol; 2020 Jan; 57(1):372-392. PubMed ID: 31364025
[TBL] [Abstract][Full Text] [Related]
34. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD
J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925
[TBL] [Abstract][Full Text] [Related]
35. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
[TBL] [Abstract][Full Text] [Related]
36. Development of autotaxin inhibitors: A series of zinc binding triazoles.
Thomson CG; Le Grand D; Dowling M; Brocklehurst CE; Chinn C; Elphick L; Faller M; Freeman M; Furminger V; Gasser C; Hamadi A; Hardaker E; Head V; Hill JC; Janus DI; Pearce D; Poulaud AS; Stanley E; Sviridenko L
Bioorg Med Chem Lett; 2018 Jul; 28(13):2279-2284. PubMed ID: 29798825
[TBL] [Abstract][Full Text] [Related]
37. The Expression Regulation and Biological Function of Autotaxin.
Zhang X; Li M; Yin N; Zhang J
Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
[TBL] [Abstract][Full Text] [Related]
38. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
40. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
